Rituximab Biosimilar Truxima Now Available for Rheumatoid Arthritis - MPR
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis | NEJM
RA | RITUXAN® (rituximab) Infusions & Dosing Schedule
RA | RITUXAN® (rituximab) Infusion Steps & Resources
![European Medicines Agency approved rituximab dosing regimens [ 10 ] . | Download Table](https://www.researchgate.net/profile/Johannes-Schmidt-15/publication/259877472/figure/tbl1/AS:601669272346676@1520460541954/European-Medicines-Agency-approved-rituximab-dosing-regimens-10_Q640.jpg "European Medicines Agency approved rituximab dosing regimens [ 10 ] . | Download Table")
European Medicines Agency approved rituximab dosing regimens [ 10 ] . | Download Table
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
RA | RITUXAN® (rituximab) Dosing Overview for Rheumatoid Arthritis
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
Eficiency of Different Doses of Rituximab in Rheumatoid Arthritis | Reumatología Clínica
Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect
Lessons for rituximab therapy in patients with rheumatoid arthritis - The Lancet Rheumatology
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text
VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating
Rituximab protocols | Download Table
RA | RITUXAN® (rituximab) Dosing Overview for Rheumatoid Arthritis
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
GPA & MPA | RITUXAN® (rituximab) Pediatric Dosing & Infusion Info
GPA & MPA | Taking & Dosing RITUXAN® (rituximab)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
Rituximab in MS | Experimental MS Treatments | Multiple Sclerosis News Today
